Nanovis
Superior Implants Powered by Nanotechnology

The winds of change have touched every industry in a way that shapes the future. Nano and other advanced technologies are now shaping the future performance of orthopedic implants. Even while some hospitals are limiting surgeon access to implants from the biggest orthopedic companies to try to capture pricing and supply chain efficiencies, most hospitals conscientiously seek out new technologies that help their patients achieve better outcomes. Committed to a mission to use cutting-edge science and nanotechnology to give hospitals and surgeons the best implant technology to heal their patients, Nanovis is a technology-driven growth company offering spine implants powered by advanced fixation technology that provides surgeons and hospitals implants with the best aspects of fixation, visualization, and durability on the market today. Nanovis’ future technology platforms promise bactericidal bone on growth surfaces and potential treatments for localized infections, even those caused by antimicrobial resistant bacteria. “Today, we aim to provide surgeons, hospitals, and their distributor partners, implants with advanced fixation technologies to help their patients heal faster and avoid fixation related surgical complications. In the future we aim to provide breakthrough solutions for bactericidal colonization and localized infections,” emphasizes Matt Hedrick, CEO of Nanovis.

“Surgeons are challenged to give their patients the best possible technology designed to improve the outcomes. Nanovis’ entire focus is to create, acquire, and commercialize technologies that truly help patients avoid the complications of surgery such as infection. We’ve invested in groundbreaking technologies that offer great promise in addressing some of the dreadful implant-related situations that patients, surgeons and hospitals have to deal with,” says Hedrick. Nanovis employs a unique strategy by accumulating so many accretive technology platforms that work together to create implant systems with exceptional fixation and bactericidal features.

Nanovis’ scientists and research collaborators are among the first to discover the use of nanosurfaces to influence tissue growth during the dawn of the field of nanomedicine, and the company has continually recruited university and industry collaborators who have the best technology in their fields to fight fixation and localized infections. Today, Nanovis has developed a series of technology platforms using deeply porous titanium scaffolds, licensed from Sites Medical, nanosurfaces on polymers such as PEEK and PEKK licensed from Purdue University, and nanotube surfaces with and without bioceramics licensed from Purdue and the University of Nevada, Reno, as well as bactericidal implant and localized infection technology developed at Nanovis.

The company is in the process of launching FortiCore spinal interbody implants, with a deeply porous titanium scaffold, enhanced with the company’s advanced nanotube and bioceramic technology, and intermolded with a PEEK core to provide the modulus, durability, and visualization surgeons want.

“The nanotube implant surface is not only an important foundation in our fixation technology portfolio, but it is also the foundation for a bactericidal surface that we are rapidly commercializing,” informs Hedrick. Nanovis utilizes its advanced nanosurfaces in creating a groundbreaking portfolio of bactericidal and bone growth surfaces to help hospitals, surgeons, and patients fight implant colonization by bacteria in the critical first 30 days after infection. “We’ve been blessed with a growing technology portfolio and our scientists are now in the process of creating a novel technology effective against antibiotic-resistant bacteria, including many particularly virulent and deadly strains, that we hope to use prevent and treat of life-threatening localized infections related to surgery and implants,” he adds. What makes Nanovis exceptional in its industry is its level of investment and focus on a biological implant science and nanotechnology-driven discovery, acquisition of early technologies, and commercializing products powered by these technologies. While the commercial potential of Nanovis’ technology portfolio appears considerable, the company also promises to help shape the future of how patients fight fixation and localized infections.